Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Are neurobiological features defining subtypes of brain dysfunction in major depressive disorder trait or state? Characterizing the determinants of familial risk and treatment remission in neurobiologically-derived subtypes of major depressive disorder.
EF 2017-18
Résumé
13-16% of Canadians will develop an episode of major depressive disorder (MDD), and conventional treatments have low recovery rates. One of the most significant barriers to improving these rates is that we lack a robust understanding of the differences between MDD patients. MDD presents differently patients, and some treatments work for some patients but not for others.
In the spirit of understanding the biological differences between MDD patients, we developed a novel method to define MDD subtypes. We showed in a large multisite sample that MDD patients can be subdivided into four subtypes defined by unique patterns of brain circuitry ("biotypes"). These biotypes predicted responsiveness in subjects who received non-invasive brain stimulation.
What we do not know, however, is whether subtype specific features of brain dysfunction predate MDD onset, nor do we know which biological features improve when MDD treatments work, and do not. Identifying such features will potentially help treat MDD two ways: first, by identifying factors that can be targeted to prevent a MDD episode; and second, by identifying residual features of brain dysfunction after treatment that can be targeted to maximize clinical efficacy.
The first aim of this proposal is to identify features of brain dysfunction in healthy individuals with a high familial risk for MDD, and to use these features to prospectively predict MDD onset at 5 and 10-years follow-up. A second aim of this proposal is to identify predictors, changes and constancies in brain dysfunction that accompany treatment response to a widely used first-line antidepressant, and to relate residual brain dysfunction to persistent clinical symptoms after treatment. I will leverage two large, pre-existing, multisite datasets with repeated measures rich with clinical, neuroimaging and psychological information to address these aims.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
373784
Name
Dunlop Katharine A
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Are neurobiological features defining subtypes of brain dysfunction in major depressive disorder trait or state? Characterizing the determinants of familial risk and treatment remission in neurobiologically-derived subtypes of major depressive disorder.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Biomarker Research; Classification - Disorder Subtypes; Depression; Fmri; Mri
Abstract
13-16% of Canadians will develop an episode of major depressive disorder (MDD), and conventional treatments have low recovery rates. One of the most significant barriers to improving these rates is that we lack a robust understanding of the differences between MDD patients. MDD presents differently patients, and some treatments work for some patients but not for others.
In the spirit of understanding the biological differences between MDD patients, we developed a novel method to define MDD subtypes. We showed in a large multisite sample that MDD patients can be subdivided into four subtypes defined by unique patterns of brain circuitry ("biotypes"). These biotypes predicted responsiveness in subjects who received non-invasive brain stimulation.
What we do not know, however, is whether subtype specific features of brain dysfunction predate MDD onset, nor do we know which biological features improve when MDD treatments work, and do not. Identifying such features will potentially help treat MDD two ways: first, by identifying factors that can be targeted to prevent a MDD episode; and second, by identifying residual features of brain dysfunction after treatment that can be targeted to maximize clinical efficacy.
The first aim of this proposal is to identify features of brain dysfunction in healthy individuals with a high familial risk for MDD, and to use these features to prospectively predict MDD onset at 5 and 10-years follow-up. A second aim of this proposal is to identify predictors, changes and constancies in brain dysfunction that accompany treatment response to a widely used first-line antidepressant, and to relate residual brain dysfunction to persistent clinical symptoms after treatment. I will leverage two large, pre-existing, multisite datasets with repeated measures rich with clinical, neuroimaging and psychological information to address these aims.
Competitiondate
201709
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dunlop, Katharine A
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~